Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Puig

Showing results (111-120 of 274) with videos related to

Pageof 28
Sort By:
Pigment Cell & Melanoma Research|June 12, 2013
Evaluation of PAX3 genetic variants and nevus numberZighereda Ogbah, Celia Badenas, Mark Harland, et al.
International Journal of Cancer|April 3, 2007
Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countriesAlisa M Goldstein, Valerie Chaudru, Paola Ghiorzo, et al.
The British Journal of Dermatology|January 30, 2019
Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatosesE Chacón-Solano, C León, F Díaz, et al.
Neurologia|August 12, 2022
The CORCOBIA study: Cut-off points of Alzheimer's disease CSF biomarkers in a clinical cohortA Puig-Pijoan, G García-Escobar, A Fernández-Lebrero, et al.
ESMO Open|April 10, 2025
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center studyA Rodriguez-Hernandez, O Martínez-Sáez, F Brasó-Maristany, et al.
ESMO Open|September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancerB Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Journal of Medical Genetics|August 15, 2006
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continentsAlisa M Goldstein, May Chan, Mark Harland, et al.
ESMO Open|March 7, 2024
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerM Marín-Aguilera, P Jares, E Sanfeliu, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world studyO Martínez-Sáez, M Tapia, M Marín-Aguilera, et al.
Cancer Research|October 19, 2006
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMELAlisa M Goldstein, May Chan, Mark Harland, et al.
Pageof 28

Showing results (111-120 of 274) with videos related to

Sort By:
Pageof 28
Pigment Cell & Melanoma Research|June 12, 2013
Evaluation of PAX3 genetic variants and nevus numberZighereda Ogbah, Celia Badenas, Mark Harland, et al.
International Journal of Cancer|April 3, 2007
Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countriesAlisa M Goldstein, Valerie Chaudru, Paola Ghiorzo, et al.
The British Journal of Dermatology|January 30, 2019
Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatosesE Chacón-Solano, C León, F Díaz, et al.
Neurologia|August 12, 2022
The CORCOBIA study: Cut-off points of Alzheimer's disease CSF biomarkers in a clinical cohortA Puig-Pijoan, G García-Escobar, A Fernández-Lebrero, et al.
ESMO Open|April 10, 2025
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center studyA Rodriguez-Hernandez, O Martínez-Sáez, F Brasó-Maristany, et al.
ESMO Open|September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancerB Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Journal of Medical Genetics|August 15, 2006
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continentsAlisa M Goldstein, May Chan, Mark Harland, et al.
ESMO Open|March 7, 2024
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerM Marín-Aguilera, P Jares, E Sanfeliu, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world studyO Martínez-Sáez, M Tapia, M Marín-Aguilera, et al.
Cancer Research|October 19, 2006
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMELAlisa M Goldstein, May Chan, Mark Harland, et al.
Pageof 28